Roche just signed a second ADC deal with China's Hansoh Pharmaceutical worth over $15 billion in potential milestones, barely a year after their first partnership. The tenfold escalation reveals how aggressively Western pharma is betting on Chinese drug innovation, geopolitics be damned.
A $15 Billion Encore
Most first dates don't lead to a second. Most licensing deals don't either. But exactly one year after partnering with China's Hansoh Pharmaceutical on a single antibody-drug conjugate (ADC), Roche came back and ordered the whole menu.
The Swiss pharma giant just signed a second, far broader ADC collaboration with Hansoh, this time covering multiple programs built on Hansoh's proprietary technology platform. The headline number: more than $15 billion in potential milestone payments, plus $400 million upfront and another $110 million due on the first anniversary. For context, the first deal last October was worth up to $1.45 billion. That's a roughly tenfold escalation in twelve months.
Something clearly impressed Roche. The question is what, and what it means for the rest of the industry.
From One Molecule to a Full Platform
The original October 2025 deal was relatively simple. Roche licensed HS-20110, a single ADC targeting a protein called CDH17, for $80 million upfront. Hansoh kept rights in Greater China; Roche got the rest of the world. Standard stuff for a China-to-West licensing arrangement.
This new deal is a different animal entirely. Instead of licensing one drug, Roche is tapping into Hansoh's entire ADC platform. Roche proposes targets, and Hansoh builds the ADCs using its proprietary linker-payload technology. Think of it like the difference between buying a single painting versus commissioning an artist to decorate your whole house.
The development split is clean: Hansoh runs early-stage clinical work through the first phase of global testing. Roche takes over from there for the rest of the world, while Hansoh keeps commercialization rights in mainland China, Hong Kong, Macau, and Taiwan. There's also an interesting wrinkle: Hansoh can choose up to two programs to co-develop outside Greater China, which could unlock additional commercialization upside in the U.S.
That co-development option is a signal. Hansoh isn't just a contract shop handing off molecules. It's positioning itself as a global player with skin in the game.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why ADCs Are the Hottest Currency in Biotech
If you've been following biotech deals in 2025 and 2026, you've noticed a pattern. ADCs are everywhere.
An antibody-drug conjugate is basically a guided missile for cancer. You take an antibody (which finds and sticks to cancer cells) and attach a toxic payload (which kills the cell). The beauty is precision: the drug goes where it's needed and spares healthy tissue. At least, that's the goal.
The concept isn't new. Roche itself has commercial ADCs like Polivy and Kadcyla. But a new wave of smarter linker chemistry and more potent payloads has supercharged the field. Chinese biotechs, in particular, have become the world's ADC factory. One recent analysis estimated that Chinese companies account for nearly 90% of global ADC licensing activity by deal count.
The result has been a gold rush of cross-border deals. Pfizer partnered with Innovent on a deal worth up to $10.5 billion. Bristol Myers Squibb signed SystImmune for up to $8.4 billion. AstraZeneca inked a deal with CSPC valued at up to $18.5 billion. Roche's $15 billion-plus headline with Hansoh now sits at the top of that pile.
The Geopolitical Elephant in the Room
All of this is happening while Washington and Beijing are still trading barbs over technology, trade, and national security. The biotech sector has its own flashpoint: ongoing discussions around legislation that could restrict U.S. government contracts with certain Chinese biotech companies. The policy environment is real, and it's making some dealmakers nervous.
But the deals keep flowing. Why? Because the science is too good to ignore.
Western pharma companies have figured out a workaround that reduces friction: they license the assets, not the companies. Roche isn't buying Hansoh or acquiring its facilities. It's licensing specific drug programs and platform access. That structure keeps the intellectual property flowing across borders while avoiding the heavier scrutiny that comes with full acquisitions.
It's a pragmatic solution. And so far, nobody is blinking.
What Hansoh's Secret Sauce Actually Is
Hansoh's ADC platform centers on topoisomerase I inhibitor payloads, which are toxic molecules that kill cancer cells by disrupting DNA replication. The company pairs these payloads with optimized cleavable linkers (the chemical bridge connecting the antibody to the toxin) designed to release the payload only when the ADC reaches its target.
For the technically curious: Hansoh's publicly known linker chemistry includes a GGFG cleavable linker paired with a proprietary payload called SHR-9265. The company's pipeline includes ADCs targeting B7-H3 (in Phase 3 in China), CDH17 (the original Roche deal), and B7-H4 (partnered with GSK).
The breadth of that pipeline, and the fact that three major Western pharma companies have now bet on it, suggests Hansoh's platform is more than a one-trick pony. Roche clearly agrees, given that this second deal is built around Hansoh's ability to generate new ADCs on demand rather than just hand over existing ones.
The $15 Billion Asterisk
Let's talk about that headline number, because it deserves a reality check. The "more than $15 billion" figure represents the theoretical maximum of all milestone payments across all programs in the deal. These milestones are tied to development, regulatory, and commercial targets that would take years (possibly decades) to fully achieve.
In practice, most mega-deals never pay out their full milestone value. Think of it like a real estate contract with an escalation clause: the ceiling is high, but you only pay more if very specific conditions are met. The $400 million upfront is real cash today. The $15 billion is aspirational math.
That said, even a fraction of $15 billion would make this one of the biggest ADC partnerships ever. And the tiered royalties on future sales could be enormously valuable if any of these programs hit.
What This Means Going Forward
Roche's repeat trip to Hansoh tells us three things.
First, Roche is rebuilding its oncology pipeline through external deals, not just internal R&D. The company has signed ADC partnerships with MediLink Therapeutics over the past two years, on top of both Hansoh deals. That's a buying spree, not a one-off.
Second, Chinese biotech innovation is being taken seriously at the highest levels. These aren't bargain-bin deals anymore. Western companies are paying hundreds of millions upfront and committing billions in milestones because the science warrants it.
Third, the ADC arms race is far from over. If Roche is willing to write a $400 million check just for platform access, the competition to lock up the best ADC technology is only going to intensify. Expect more deals, bigger numbers, and more companies racing to turn cancer's guided missiles into blockbuster drugs.
Roche went back for seconds. Don't be surprised if it goes back for thirds.
Clinical & Regulatory
4 min read
Gilead Just Crashed the Biggest Party in Gastroenterology
Gilead's ulcerative colitis pill posted mid-stage results that beat Wall Street expectations, with remission rates nearly four times higher than placebo. The HIV giant just served notice to AbbVie, Takeda, and every other player in the $25 billion IBD market.
